Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT06318234
Eligibility Criteria:
Inclusion Criteria:
* Pathologically confirmed as rectal adenocarcinoma, with baseline clinical staging of T3\~4 and/or N+;
* No distant metastasis;
* Not receiving chemotherapy or any other anti-tumor treatment before enrollment;
* Has not received immunotherapy before enrollment and is able to adhere to the protocol during the study period (neoadjuvant therapy of short-term radiotherapy sequential chemotherapy combined with immunotherapy);
* After neoadjuvant therapy, 18F-FAPI and 18F-FDG PET/MRI imaging were performed within 7 days before surgery, and the two scans were collected over two days;
* Patient age ≥ 18 years old
Exclusion Criteria:
* Pregnant or lactating patients;
* Patients with severe heart disease in clinical practice;
* Organ transplantation requires immunosuppressive therapy and long-term use of hormone therapy;
* Patients with autoimmune diseases;
* Serious uncontrolled recurrent infections or other serious uncontrolled comorbidities;
* The imaging quality is poor and cannot be used for diagnosis and evaluation;
* Fasting blood glucose levels are higher than 11.1 mmol/L;
* Patients with contraindications for MRI examination.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06318234
Study Brief:
Protocol Section:
NCT06318234